H.C. Wainwright Reiterates Buy Rating on Marker Therapeutics (MRKR)
H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $10.00 price target on Marker Therapeutics (NASDAQ: MRKR).The analyst commented ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
